Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 4 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.

Rosuvastatin improves coagulation profile of patients with prior thrombosis

Pearl Toh
17 Aug 2017

Rosuvastatin led to improved coagulation profile, in particular lower levels of factor VIII procoagulant activity (VIII:C), among patients who had venous thrombosis (VT) previously, suggesting that statins could reduce the risk of recurrent VT, according to a study presented at the ISTH 2017 Congress in Berlin, Germany.

The study randomized 247 participants (mean age 58 years, 62 percent women), with prior VT and who recently stopped their anticoagulant therapy, to receive rosuvastatin 20 mg/day for 4 weeks or no intervention. Five coagulation factors ─ factor VIII:C, factor VII:C, factor XI:C, von Willebrand factor (VWF:Ag), and D-dimer were measured through blood test at baseline and at the end of the study. [ISTH 2017, abstract LB03]

Mean factor VIII:C ─ the primary endpoint and for which the study was powered ─ was 7.2 IU/dL lower (95 percent confidence interval [CI], -11.5 to -2.9) than baseline in the rosuvastatin arm, while there was no change from baseline in the control arm (mean difference, -0.1 IU/dL, 95 percent CI, -3.0 to 2.9). 

After adjusting for age and sex, the reduction in factor VIII:C from baseline remained greater in rosuvastatin users vs nonusers (adjusted difference, -6.7 IU/dL, 95 percent CI, -12.0 to -1.4).

Among 52 rosuvastatin users with high factor VIII:C at baseline (>150 IU/dL), the elevated levels were normalized in 15 participants at the end of study, equivalent to a 12 percent decrease in the percentage of patients with elevated levels.

In contrast, the proportion of patients with high factor VIII:C levels was the same between baseline and end of study among nonusers.

For all the other coagulation factors tested, the mean coagulant activity from baseline was also lower or trended towards lower levels at the end of study in the rosuvastatin compared with the control arms.

“These results encourage conducting a randomized trial to determine whether statin therapy is a good alternative for long term anticoagulant treatment when it reduces the risk of recurrent VT without inducing bleeding,” according to the researchers.

The findings were in keeping with previous observational studies, which indicate that statins may reduce the risk of recurrent VT. One such study is the MESA* study, which showed that the levels of factor VIII, D-dimer, and C-reactive protein were lower among healthy participants who were on statins compared with those who did not take statins. [J Thromb Haemost 2013;11:1078-1084]

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
Pearl Toh, 4 days ago
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
01 Jan 2012
A phase III, open-label, single-centre study presents the suitability of DTaP-IPV//PRP-T booster following primary vaccination with DTaP-IPV-Hep B-PRP-T vaccine.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.